Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Dihexa | PT-141 (Bremelanotide) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 10-20 mg daily via oral or sublingual administration. | Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity. |
| Timing | Morning dosing preferred. Can be taken with or without food (orally active). | 45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response. |
| Cycle Duration | 2-4 week cycles with equal rest periods. Long-term safety data is extremely limited. | As-needed basis. Not intended for daily use. |
| Evidence Level | animal_plus_anecdotal | strong_human |
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is an orally active, blood-brain barrier-permeable oligopeptide derived from angiotensin IV. It binds hepatocyte growth factor (HGF) with high affinity, inhibiting HGF dimerization and synergistically promoting c-Met receptor phosphorylation and signaling. Activation of HGF/c-Met drives procognitive effects through increased dendritic arborization, spinogenesis, and synaptogenesis via the PI3K/AKT signaling pathway. Research indicates it is approximately 10 million times more potent than BDNF for new synapse formation.
Research indicates 10-20 mg daily via oral or sublingual administration.
Morning dosing preferred. Can be taken with or without food (orally active).
2-4 week cycles with equal rest periods. Long-term safety data is extremely limited.
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin analog that acts as an agonist at MC3R and MC4R melanocortin receptors, with higher affinity for MC4R. It enhances sexual desire by activating presynaptic MC4Rs on neurons in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release — an excitatory neurotransmitter for sexual desire. Unlike PDE5 inhibitors, PT-141 works centrally through the CNS rather than peripherally on blood flow, addressing desire rather than just erectile mechanics.
Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.
45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.
As-needed basis. Not intended for daily use.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →